immunotherapy

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.

Every year cancer kills eight million people worldwide. By 2030, the number of annually diagnosed cases will exceed 21.7 million resulting in 13 million cancer deaths due to aging and population growth. Join the fight against cancer by embarking on a research mission to develop a personalized immunotherapy using augmented reality.

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.